Search results
Results from the WOW.Com Content Network
Gynecomastia is the most common benign disorder of the male breast tissue and affects 35 percent of men, being most prevalent between the ages of 50 and 69. [5] [9] New cases of gynecomastia are common in three age populations: newborns, adolescents, and men older than 50 years. [58]
Androgen deficiency is a medical condition characterized by insufficient androgenic activity in the body. Androgen deficiency most commonly affects women, and is also called Female androgen insufficiency syndrome (FAIS), although it can happen in both sexes.
It is also one of the signs of CHARGE syndrome. Examples of acquired causes of hypogonadism: [citation needed] Opioid Induced Androgen Deficiency (resulting from the prolonged use of opioid class drugs, e.g. codeine, Dihydrocodeine, morphine, oxycodone, methadone, fentanyl, hydromorphone, etc.) Anabolic steroid-induced hypogonadism (ASIH)
Antiestrogens include selective estrogen receptor modulators (SERMs) like tamoxifen, clomifene, and raloxifene, the ER silent antagonist and selective estrogen receptor degrader (SERD) fulvestrant, [6] [7] aromatase inhibitors (AIs) like anastrozole, and antigonadotropins including androgens/anabolic steroids, progestogens, and GnRH analogues.
Estrogenic side effects such as gynecomastia and fluid retention can also occur. [1] Case reports of gynecomastia exist. [ 21 ] [ 22 ] As with other 17α-alkylated steroids, methandienone poses a risk of hepatotoxicity and use over extended periods of time can result in liver damage without appropriate precautions.
Sources: See template. Androstanolone is a potent agonist of the AR. It has an affinity (K d ) of 0.25 to 0.5 nM for the human AR, which is about 2- to 3-fold higher than that of testosterone (K d = 0.4 to 1.0 nM) [ 41 ] and the dissociation rate of androstanolone from the AR is also about 5-fold slower than that of testosterone. [ 42 ]
This is a list of androgens/anabolic steroids (AAS) or testosterone derivatives. Androgen esters are mostly not included in this list. The major classes of testosterone derivatives include the following (as well as combinations thereof):
A small risk of gynecomastia has been associated with 5α-reductase inhibitors (1.2–3.5%). [36] [41] Based on reports of 5α-reductase type 2 deficiency in males and the effectiveness of 5α-reductase inhibitors for hirsutism in women, reduced body and/or facial hair growth is a likely potential side effect of these drugs in men.